All 1 tracked stories fall under one category: gene-therapy. Of the tracked stories, 1 of 1 also mention Broadcom, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about RP-A501
All 1 tracked stories fall under one category: gene-therapy. Of the tracked stories, 1 of 1 also mention Broadcom, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6 in the same window. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. We currently track 1 Biotech story that mention RP-A501, all published on March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering RP-A501. Shared-story counts are live from our verified record — not editorial picks.
Rocket Pharmaceuticals (RCKT) shares declined 4.4% on March 19, 2026, as investors weighed a recent shift in the company's financial agreements against ongoing regulatory timelines for its lead gene therapy programs. The drop outpaced broader market movements, reflecting specific volatility in the rare disease gene therapy sector.